5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis
Issued Date
2024-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85188945064
Journal Title
Scientific Reports
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.14 No.1 (2024)
Suggested Citation
Meevassana J., Varophas S., Prabsattru P., Kamolratanakul S., Ruangritchankul K., Kitkumthorn N. 5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis. Scientific Reports Vol.14 No.1 (2024). doi:10.1038/s41598-024-58011-z Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97868
Title
5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis
Corresponding Author(s)
Other Contributor(s)
Abstract
There is a correlation between DNA methylation and the diseased stage and poor survival. 5-methylcytosine (5-mC) is one of the epigenetic modifications of bases that researchers focus on. Staining with 5-mC immunohistochemistry was used to examine pathological samples taken from individuals diagnosed with cutaneous melanoma. Between Breslow levels 2 and 4, there was a significant difference in the H-score of 5-mC expression (p = 0.046). A significant reduction in 5-mC expression H-scores was seen in patients who were diagnosed with ulcers (p = 0.039). It was shown that patients with low 5-mC had a significantly worse overall survival rate (p = 0.027).